Na Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Jiang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Lin Sun
Department of Nephrology, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, China
3 shared publications - Shan Xiong
Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China;; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, China;; National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
3 shared publications - Chenrui Li
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
2 shared publications - Hao Zhao
Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
2 shared publications - Ling Wei
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
2 shared publications - Lingfeng Zeng
Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
2 shared publications
Latest Publications
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (14) , 2717-2728
Mitophagy: A Novel Therapeutic Target for Treating DN
Diabetic nephropathy (DN) is a common microvascular complication of diabetes and one of the leading causes of end-stage renal disease. Tubular damage is an early change and characteristic of DN, and mitochondrial dysfunction plays an important role in the development of DN. Therefore, the timely removal of damaged mitochondria in tubular cells is an effective treatment strategy for DN. Mitophagy is a type of selective autophagy that ensures the timely elimination of damaged mitochondria to protect cells from oxidative stress. In this review, we summarize our understanding of mitochondrial dysfunction and dynamic disorders in tubular cells in DN and the molecular mechanism of mitophagy. Finally, the role of mitophagy in DN and its feasibility as a therapeutic target for DN are discussed.
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (14) , 2717-2728
Mitophagy: A Novel Therapeutic Target for Treating DN
Diabetic nephropathy (DN) is a common microvascular complication of diabetes and one of the leading causes of end-stage renal disease. Tubular damage is an early change and characteristic of DN, and mitochondrial dysfunction plays an important role in the development of DN. Therefore, the timely removal of damaged mitochondria in tubular cells is an effective treatment strategy for DN. Mitophagy is a type of selective autophagy that ensures the timely elimination of damaged mitochondria to protect cells from oxidative stress. In this review, we summarize our understanding of mitochondrial dysfunction and dynamic disorders in tubular cells in DN and the molecular mechanism of mitophagy. Finally, the role of mitophagy in DN and its feasibility as a therapeutic target for DN are discussed.
- Open Access
- 7 August 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-15
AdipoRon Protects against Tubular Injury in Diabetic Nephropathy by Inhibiting Endoplasmic Reticulum Stress
Endoplasmic reticulum (ER) stress has been reported to play a pivotal role in diabetic nephropathy (DN). AdipoRon is a newly developed adiponectin receptor agonist that provides beneficial effects for diabetic mice; however, its underlying mechanism remains to be delineated. Here, we demonstrated increased expression levels of ER stress markers, accompanied by upregulated levels of proinflammatory cytokines and increased expression of collagen I, fibronectin, Bax, and cleaved caspase 3 in the kidneys of db/db mice compared with control mice. Decreased expression of adiponectin receptor 1 (AdipoR1) and phosphorylated 5AMP-activated kinase (p-AMPK) was also observed in the kidneys of db/db mice. However, these alterations were partially reversed by intragastric gavage with AdipoRon. In vitro, AdipoRon alleviated high-glucose-induced ER stress, oxidative stress, and apoptosis in HK-2 cells, a human tubular cell line. Moreover, AdipoRon restored the expression of AdipoR1 and p-AMPK in HK-2 cells exposed to high-glucose conditions. Additionally, these effects were partially abrogated by pretreatment with AdipoR1 siRNA, but this abrogation was ameliorated by cotreatment with AICAR, an AMPK activator. Furthermore, the effects of AdipoRon were also partially abolished by cotreatment with compound C. Together, these results suggest that AdipoRon exerts favorable effects on diabetes-induced tubular injury in DN by inhibiting ER stress mediated by the AdipoR1/p-AMPK pathway.- 7 August 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-15
Open AccessAdipoRon Protects against Tubular Injury in Diabetic Nephropathy by Inhibiting Endoplasmic Reticulum Stress
Endoplasmic reticulum (ER) stress has been reported to play a pivotal role in diabetic nephropathy (DN). AdipoRon is a newly developed adiponectin receptor agonist that provides beneficial effects for diabetic mice; however, its underlying mechanism remains to be delineated. Here, we demonstrated increased expression levels of ER stress markers, accompanied by upregulated levels of proinflammatory cytokines and increased expression of collagen I, fibronectin, Bax, and cleaved caspase 3 in the kidneys of db/db mice compared with control mice. Decreased expression of adiponectin receptor 1 (AdipoR1) and phosphorylated 5AMP-activated kinase (p-AMPK) was also observed in the kidneys of db/db mice. However, these alterations were partially reversed by intragastric gavage with AdipoRon. In vitro, AdipoRon alleviated high-glucose-induced ER stress, oxidative stress, and apoptosis in HK-2 cells, a human tubular cell line. Moreover, AdipoRon restored the expression of AdipoR1 and p-AMPK in HK-2 cells exposed to high-glucose conditions. Additionally, these effects were partially abrogated by pretreatment with AdipoR1 siRNA, but this abrogation was ameliorated by cotreatment with AICAR, an AMPK activator. Furthermore, the effects of AdipoRon were also partially abolished by cotreatment with compound C. Together, these results suggest that AdipoRon exerts favorable effects on diabetes-induced tubular injury in DN by inhibiting ER stress mediated by the AdipoR1/p-AMPK pathway. - Open Access
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Open AccessAristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.
- Open Access
- 13 August 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 6 (5) , 1075-1080
Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times
Cisplatin (cis-diamminedichloroplatinum, CDDP) is one of the most potent anticancer drugs. However, the therapeutic value of CDDP is greatly compromised by its dose-limiting nephrotoxicity. This study was performed to investigate whether reduced glutathione (GSH) was able to reduce the kidney injury induced by CDDP and whether it affected the anticancer activity of CDDP in vivo and in vitro. In in vivo experiments, mice were divided into five groups: control, CDDP only and three GSH treatment groups. Blood samples were collected 72 h after CDDP administration to determine the levels of blood urea nitrogen (BUN) and plasma creatinine (Cr). In addition, we examined antioxidative parameters, malondialdehyde (MDA) levels and histopathological changes in the kidney. In order to investigate whether GSH affected the anticancer activity of CDDP, we performed a sulforhodamine B (SRB) assay to determine the anti-proliferative effect in three tumor cell lines of treatment with CDDP alone or combined with GSH and examined the cell morphology. The results revealed that GSH decreased the BUN and Cr levels in plasma, ameliorated the pathological changes induced by CDDP and enhanced the endogenous antioxidant capacities in all three GSH groups. Furthermore, GSH significantly inhibited the growth of the three tumor cell lines when combined with CDDP and did not affect the inhibitory effect of CDDP on the carcinoma cell proliferation. In addition, we found no differences among the three GSH groups. These findings suggest that GSH is able to attenuate the nephrotoxicity induced by CDDP, not only when administered prior to CDDP, but also when administered at the same time as or subsequent to CDDP administration, without affecting the anticancer activity of CDDP. Thus, the administration of GSH is a promising approach for attenuating the nephrotoxicity caused by CDDP.
- 13 August 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 6 (5) , 1075-1080
Open AccessEvaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times
Cisplatin (cis-diamminedichloroplatinum, CDDP) is one of the most potent anticancer drugs. However, the therapeutic value of CDDP is greatly compromised by its dose-limiting nephrotoxicity. This study was performed to investigate whether reduced glutathione (GSH) was able to reduce the kidney injury induced by CDDP and whether it affected the anticancer activity of CDDP in vivo and in vitro. In in vivo experiments, mice were divided into five groups: control, CDDP only and three GSH treatment groups. Blood samples were collected 72 h after CDDP administration to determine the levels of blood urea nitrogen (BUN) and plasma creatinine (Cr). In addition, we examined antioxidative parameters, malondialdehyde (MDA) levels and histopathological changes in the kidney. In order to investigate whether GSH affected the anticancer activity of CDDP, we performed a sulforhodamine B (SRB) assay to determine the anti-proliferative effect in three tumor cell lines of treatment with CDDP alone or combined with GSH and examined the cell morphology. The results revealed that GSH decreased the BUN and Cr levels in plasma, ameliorated the pathological changes induced by CDDP and enhanced the endogenous antioxidant capacities in all three GSH groups. Furthermore, GSH significantly inhibited the growth of the three tumor cell lines when combined with CDDP and did not affect the inhibitory effect of CDDP on the carcinoma cell proliferation. In addition, we found no differences among the three GSH groups. These findings suggest that GSH is able to attenuate the nephrotoxicity induced by CDDP, not only when administered prior to CDDP, but also when administered at the same time as or subsequent to CDDP administration, without affecting the anticancer activity of CDDP. Thus, the administration of GSH is a promising approach for attenuating the nephrotoxicity caused by CDDP.